Industry News
DPI attracts international scientist
As part of a major scientific collaboration, the Department of Primary Industries (DPI) has appointed Canadian scientist, Dr Kim Lowell.
[ + ]Solbec granted patent
Solbec Pharmaceuticals (ASX:SBP) has been granted an Australian patent giving the company the monopoly right to prevent others from isolating the rhamnose binding protein receptor of its lead compound Coramsine. [ + ]
Phylogica patent allowed
Perth-based Phylogica (ASX:PYC) has received formal notice of allowance from the European Patent and Trademark Office for its pending patent application entitled: "Isolating biological modulators from biodiverse gene fragment libraries". [ + ]
Swinburne develops CD analysis method to aid bioterrorism fight
Melbourne's Swinburne University of Technology has developed a rapid method for the analysis of microorganisms on CD or DVD which could be used to detect bioterror agents. [ + ]
Norwood Immunology granted six patents
Melbourne immune therapy developer Norwood Immunology (AIM:NIL) has been granted six patents in New Zealand, South Africa and Singapore relating to its technology in key areas such as cancer and infectious diseases. [ + ]
Citrofresh quashes HIV orange cure talk
Geelong-based disinfectant maker Citrofresh International (ASX:CTF), which caused a stock frenzy with news of a cure-all ingredient found in oranges, has dashed investors' hopes it had a vaccine against HIV, SARS, flu and the common cold. [ + ]
Apollo acquires pre-clinical testing facility
Recently listed Sydney biopharma Apollo Life Sciences (ASX:AOP) has acquired a fully operational pre-clinical testing facility in Sydney, including equipment and staff with expertise in targeted and topical drug delivery. [ + ]
Bone Medical aims to raise $3.1 million
Bone disease biopharmaceutical company Bone Medical (ASX:BNE) has issued a prospectus with the aim of raising approximately AUD$3.1 million. [ + ]
Promising opening for Giaconda
Sydney-based gastrointestinal drug development company Giaconda (ASX:GIA) has listed today on the Australian Stock Exchange at AUD$0.585, eight cents above its issue price of $0.50. [ + ]
Chemgenex expands trial to include breast and ovarian cancers
Melbourne and California-based ChemGenex Pharmaceuticals (ASX:CXS) has expanded phase II clinical trials of its investigational anti-cancer drug Quinamed to include patients with breast and ovarian cancer. [ + ]
NeuroSolutions signs $100,000 contract
UK-based NeuroSolutions, the fully owned subsidiary of neurology-focused biotech NeuroDiscovery (ASX:NDL), is to receive about AUD$100,000 for providing electrophysiology services to drug development company Senexis over the next four months. [ + ]
Acrux granted four US patents, licensee meets with FDA
Acrux (ASX:ACR) has been granted four more US patents relating to its transdermal drug delivery technology. [ + ]
Box Hill Institute hires former AusBiotech CEO
Melbourne TAFE college Box Hill Institute (BHI) has engaged former AusBiotech executive director and CEO Dr Anthony Coulepis to advise on the delivery of education and training through its recently launched BioSkills initiative. [ + ]
Delays extend Prima-AstraZeneca partnership
AstraZeneca has agreed to extend the completion date for a validation study of Prima Biomed (ASX:PRR) subsidiary Arthron's anti-inflammatory Fc receptor target. [ + ]
Bird flu: threat to Australia 'unlikely'
An Australian expert on influenza believes it is unlikely that migratory birds will carry Asia's lethal H5N1 'bird 'flu' strain to Australia. [ + ]
